| Literature DB >> 25889814 |
Chen Jiang1,2,3, Jun Sun4,5,6, Yafei Dai7,8,9, Pengfei Cao10,11,12, Liyang Zhang13, Shuping Peng14,15, Yanhong Zhou16,17, Guiyuan Li18,19,20, Jingqun Tang21, Juanjuan Xiang22,23,24.
Abstract
INTRODUCTION: Bone marrow-derived mesenchymal stem cells (BMSCs, also known as bone marrow-derived mesenchymal stromal cells) are known to be a component of the tumor microenvironment. BMSCs are multipotent stromal cells that can differentiate into a variety of cell types, including osteocytes, chondrocytes, adipocytes, epithelial cells and endothelial cells. Stem cells found in niches or transplanted into injured tissues constantly encounter hypoxic stress. Areas with very low to no oxygen pressure exist in solid tumors. The differentiation capacity of BMSCs under hypoxic conditions remains controversial.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25889814 PMCID: PMC4559195 DOI: 10.1186/s13287-015-0014-4
Source DB: PubMed Journal: Stem Cell Res Ther ISSN: 1757-6512 Impact factor: 6.832
PCR primers used for luciferase constructs
|
|
|
| |
|---|---|---|---|
| LPL | 5′-TACTCGAGATGTGCATGCCTCTTA-3′ | 5′-ATAAGCTTCAGGGCTTTGCTCTCC-3′ | 1,179 |
| CFD | 5′-TCCTCGAGTGACTCTGTTCATCAGAAC-3′ | 5′-GTAAGCTTCTACACAGCCCTGTCCCTC-3′ | 989 |
| HIG2 | 5′-TCCTCGAGTCTTTAGTTC AAGCCG-3′ | 5′-ATAAGCTTCCGGAGGAAA GTCGGT-3′ | 1,008 |
| PGAR | 5′-GACTCGAGAAAGTCTCTCCTGGTC-3′ | 5′-ACAAGCTTGTTCCAGGTGCGAGGA-3′ | 969 |
| C/EBPδ | 5′-TGCTCGAGATCTGCTCTGCTTT-3′ | 5′-TCAAGCTTTGGAGTCGATGTAGGCG-3′ | 1,001 |
| Leptin | 5′-TACTCGAGATCATGTAAA GCGGGG-3′ | 5′-GCAAGCTTCAAGAAAGACCAGAGA-3′ | 918 |
PCR primers used for gene expression
|
|
| |
|---|---|---|
| OPN | 5′-TTGCAGTGATTTGCTTTTGC-3′ | 5′-GCCACAGCATCTGGGTATTT-3′ |
| OCN | 5′-GACTGTGACGAGTTGGCTGA-3′ | 5′-CTGGAGAGGAGCAGAACTGG-3′ |
| ALP | 5′-CCACGTCTTCACATTTGGTG-3′ | 5′-GCAGTGAAGGGCTTCTTGTC-3′ |
| PGAR | 5′-TGCAAGATGACCTCAGATGG-3′ | 5′-CCATGATGCTATGCACCTTC-3′ |
| HIG2 | 5′-CCACAGTGCAAGACTCCATC-3′ | 5′-GCCATACTGCTGAGGAAAGC-3′ |
| PPARγ | 5′-GAGCCCAAGTTTGAGTTTGC-3′ | 5′-CTGTGAGGACTCAGGGTGGT-3′ |
| LPL | 5′-AGTGGCCAAATAGCACATCC-3′ | 5′-CCGAAAGATCCAGAATTCCA-3′ |
| β-actin | 5′-ACTGGAACGGTGAAGGTGAC-3′ | 5′-AGAGAAGTGGGGTGGCTTTT-3′ |
Figure 1Phenotypic analysis of bone marrow-derived mesenchymal stem cells. (A) Bone marrow-derived mesenchymal stem cells (BMSCs) were analyzed by flow cytometry analysis for the surface expression of CD34, CD44, CD45, CD105 and CD11B. (B) BMSCs were tested for their differentiation potential into osteocytes and adipocytes when cultured in differentiation media. Alizarin red staining and Oil red O staining were performed. (I) Alizarin red S staining showed calcium deposition (red). (II) Oil red O staining revealed lipid droplets (red) in adipocyte-differentiated mesenchymal stem cells. Magnification: 200 ×.
Figure 2Bone marrow-derived mesenchymal stem cells show potential to differentiate into adipocytes. (A) Alkaline phosphatase staining showed less blue-stained osteocytes in bone marrow-derived mesenchymal stem cells (BMSCs) treated under hypoxia (magnification: 100×). (B) Oil red O staining revealed that the lipid accumulation in BMSCs was significantly higher under hypoxic conditions than normoxic conditions (magnification: 100×). (C) Real-time PCR assays showed that hypoxia decreased the mRNA expression of the osteoblast marker genes ALP, OPN and osteocalcin. Cells were treated in a hypoxic chamber for 3 days. (D) Real-time PCR results showed increased mRNA expression of the adipocyte-associated genes leptin, LPL, CFD, HIG2 and PGAR. Cells were treated in a hypoxic chamber for 3 days. (E) Seven days after treatment, Oil red O staining revealed that the lipid accumulation in BMSCs was significantly higher under hypoxic conditions than normoxic conditions. (F) Fourteen days after treatment, Oil red O staining revealed that the lipid accumulation in BMSCs was significantly higher under hypoxic conditions than normoxic conditions. (G) BMSCs showed characteristics of mature adipocytes after long-term hypoxic treatment. Real-time PCR results showed increased mRNA expression of leptin, HIG2 and PGAR after 7 days of hypoxic treatment. (H) Real-time PCR results showed increased mRNA expression of leptin, HIG2 and PGAR after 14 days of hypoxic treatment. In contrast, the early markers of adipocytes such as LPL were expressed at lower levels in BMSCs under hypoxia compared with that of BMSCs treated with adipogenic differentiation media under normoxia after long-term hypoxic treatment. *p <0.05; **p <0.01.
Figure 3HIF-1A regulates the adipogenic differentiation of bone marrow-derived mesenchymal stem cells. (A) Stable hypoxia-inducible factor 1 alpha (HIF-1A) suppression in bone marrow-derived mesenchymal stem cells (BMSCs) was established using lentivirus-based delivery. (B) Oil red O staining revealed that BMSCs with knockdown of HIF-1A under hypoxic conditions showed less formation of lipid oil (magnification: 100×). (C) Real-time PCR results showed that hypoxia in the HIF-1A knockdown BMSCs induced decreased expression of HIG2 and PGAR compared with BMSCs expressing wild-type HIF-1A. (D) Oil red O staining showed intracellular lipid droplet accumulation after electroporation of a HIF-1A construct (magnification: 100×). (E) Real-time PCR assays showed that electroporation-mediated HIF-1A overexpression in mesenchymal stem cells induced the expression of HIG2 and PGAR, but not LPL. **p <0.01; ***p <0.001.
Figure 4Gene expression profiling of bone marrow-derived mesenchymal stem cells under hypoxic conditions. An RT2 Profiler™ PCR Array (Sabioscience, Shanghai, China) was used to screen a panel of 84 genes associated with human adipogenesis in bone marrow-derived mesenchymal stem cells (BMSCs) under normal and hypoxic conditions. (A) Scatter plot of upregulation and downregulation of all of the investigated genes. Black line, fold change [(2^(∆∆Ct)]. (B) Ten genes were upregulated and 11 genes were downregulated by twofold in BMSCs under 0.2% oxygen compared with those under 21% oxygen. (C) The interactive network during adipogenesis.
Figure 5Adipogenic differentiation of bone marrow-derived mesenchymal stem cells (BMSCs) is regulated by a C/EBP-mediated pathway and PPARγ exerts a negative effect on differentiation of BMSCs into adipocytes. (A, B) Adipogenic differentiation of bone marrow-derived mesenchymal stem cells (BMSCs) is peroxisome proliferator activated receptor gamma (PPARγ) independent. (A) Oil red O staining revealed that BMSCs treated with the PPARγ inhibitor GW9662 under hypoxic conditions instead showed increased lipid droplet accumulation (magnification: 100×). (B) Real-time PCR assays showed that PPARγ inhibition with GW9662 induced HIG2 and LPL expression. (C, D) CCAAT enhancer-binding proteins (C/EBPs) induced the adipogenic differentiation of BMSCs in hypoxia. (C) Oil red O staining revealed that BMSCs treated with the C/EBP inhibitor betulinic acid under hypoxic conditions showed less lipid droplet accumulation (magnification: 100×). (D) Real-time PCR assays showed that C/EBP inhibition with betulinic acid inhibited leptin and CFD expression.
Figure 6HIF-1A and C/EBPs transcriptionally regulate the expression of adipocyte-specific genes. (A) Predicted binding sites of hypoxia-inducible factor 1 alpha (HIF-1A; blue boxes) and CCAAT enhancer-binding proteins (C/EBPs; red boxes) in the sequence approximately 1 kb upstream of the transcription start sites (TSSs). Luciferase activity was measured 48 hours after transfection. Co-transfection with a HIF-1A expression vector markedly increased the reporter expression rate of leptin, HIG2 and PGAR. Co-transfection with a C/EBPδ expression vector markedly increased the reporter expression rate of leptin, PGAR, CFD and LPL. HIF-1A and C/EBPβ coordinately upregulated the promoter activities of leptin and HIG2. The expression of leptin was also coordinately upregulated by HIF-1A and C/EBPδ. (B) Chromatin immunoprecipitation analysis of HIF-1A or C/EBPδ binding to the promoters was conducted. DNA released from the precipitated complexes was amplified by PCR and the PCR products were separated by agarose gel electrophoresis. Lane 1, DNA ladder; lanes 2 to 6, HIF-1A antibody or C/EBPδ antibody pull-down; lane 7, anti-RNA polymerase II; lane 8, immunoglobulin G control; lanes 9 to 13, input.